Global Blood Therapeutics, Inc. (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 140,055 shares of the company’s stock, valued at $4,201,650. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jung Choi also recently made the following trade(s):

  • On Thursday, August 31st, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $90,000.00.
  • On Friday, July 21st, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $90,000.00.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) traded down 0.16% during trading on Monday, reaching $31.00. The company had a trading volume of 1,314,544 shares. The stock has a 50 day moving average of $27.87 and a 200-day moving average of $30.05. The company’s market capitalization is $1.35 billion. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same quarter last year, the business posted ($0.58) earnings per share. Equities research analysts expect that Global Blood Therapeutics, Inc. will post ($2.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics, Inc. (GBT) Insider Jung Choi Sells 3,000 Shares” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/02/global-blood-therapeutics-inc-gbt-insider-jung-choi-sells-3000-shares.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC boosted its position in Global Blood Therapeutics by 19.3% during the fourth quarter. Teachers Advisors LLC now owns 29,682 shares of the company’s stock worth $429,000 after purchasing an additional 4,812 shares during the period. Russell Investments Group Ltd. grew its holdings in Global Blood Therapeutics by 1,054.6% during the first quarter. Russell Investments Group Ltd. now owns 28,761 shares of the company’s stock valued at $1,060,000 after purchasing an additional 26,270 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Global Blood Therapeutics by 25.3% during the first quarter. Wells Fargo & Company MN now owns 120,568 shares of the company’s stock valued at $4,443,000 after purchasing an additional 24,363 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Global Blood Therapeutics during the first quarter valued at approximately $129,000. Finally, Bank of New York Mellon Corp grew its holdings in Global Blood Therapeutics by 79.2% during the first quarter. Bank of New York Mellon Corp now owns 139,389 shares of the company’s stock valued at $5,137,000 after purchasing an additional 61,593 shares during the last quarter. Institutional investors own 86.07% of the company’s stock.

A number of analysts recently issued reports on GBT shares. BidaskClub downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company restated an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a report on Monday, August 14th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $46.00 price target (up from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. Needham & Company LLC began coverage on shares of Global Blood Therapeutics in a research report on Wednesday, September 20th. They set a “buy” rating and a $51.00 price target on the stock. Finally, ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $52.27.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.